Cyclic Vomiting Syndrome (CVS) in Adults: Diagnosis, Triggers, Treatment

If you have stereotypical episodes of severe vomiting that come on suddenly, last hours to days, and then resolve completely until the next one, you have probably been told it is gastroenteritis, anxiety, gastroparesis, or unexplained vomiting. You may have been to the emergency department five or ten or fifteen times. Each visit looks like an isolated event because the workup is normal between episodes. This is what cyclic vomiting syndrome looks like in adults, and it is the reason the average diagnostic delay from first episode to confirmed CVS diagnosis sits between five and nine years in published case series. This guide walks through what CVS is, how the Rome IV criteria define it, what triggers it, why cannabis hyperemesis syndrome must be ruled out first, the abortive protocol most ER teams have not been trained on, the prophylactic medications with the strongest evidence, and the honest, narrow place where gut-directed hypnotherapy can sit alongside that medical management as an adjunct.

Cyclic vomiting syndrome is a chronic functional gut-brain disorder characterised by recurrent, stereotypical episodes of severe nausea and vomiting that come on suddenly, last hours to days, and resolve completely. Between episodes the patient is, by definition, symptom-free. This is the feature that most distinguishes CVS from chronic nausea, gastroparesis, and other ongoing functional gut disorders: CVS is episodic, not continuous. The technical home of CVS in the Rome IV classification is the section on functional gastroduodenal disorders, alongside functional dyspepsia and chronic nausea and vomiting syndrome. CVS sits in its own category because the episodic, stereotypical pattern is unusual enough to deserve a separate label and a separate management algorithm.

The episodes are usually severe. Patients describe vomiting many times an hour at peak intensity, profuse retching even when the stomach is empty, intense thirst they cannot satisfy because anything that goes down comes back up, and a level of incapacity that ranks among the worst things they have experienced. Many patients describe a strong preference for a dark, quiet room and find any sensory input intolerable during the acute phase. This is one of the features that points toward the migraine link, and it is also part of why the published abortive protocols emphasise environment as well as medication.

CVS was first described in pediatric medicine in the late nineteenth century and was thought of as a childhood condition for most of the twentieth century. The recognition that adult CVS is a distinct entity, not a misdiagnosis of something else, came later and is still incomplete in general adult practice. Pediatric gastroenterology continues to recognise and treat CVS more readily than adult gastroenterology in many health systems. This is part of why adult patients often experience a long diagnostic delay. The clinicians most familiar with the pattern are usually not the ones the adult patient is sent to first.

One critical adjacent condition that needs to be on the table from the start is cannabis hyperemesis syndrome (CHS). CHS produces a clinically very similar episodic vomiting pattern but is caused by chronic cannabis use, typically daily or near-daily for at least one to two years. With cannabis legalisation in Canada and parts of the United States, CHS has become substantially more common in adult emergency departments and now accounts for a meaningful fraction of presentations that look like CVS. The two conditions are often confused, and the management is completely different. CHS resolves with sustained cannabis cessation, usually within one to three months. CVS does not. This is why every adult work-up for cyclic vomiting needs an explicit, non-judgmental cannabis history before any prophylactic medication is prescribed.

CVS is also commonly misdiagnosed as recurrent gastroenteritis (each episode looks like a stomach bug to a clinician seeing the patient once), gastroparesis (because gastric emptying may be slow during or after an episode), unexplained vomiting (a placeholder rather than a diagnosis), or anxiety-driven vomiting (which dismisses the patient and misses the underlying biology). Each of these labels delays the right management. The path forward is the pattern: stereotypical, severe, self-limited, with symptom-free intervals. When that pattern is named, the rest of the management algorithm follows.

The practical reason this matters in clinic is that the episode arc is itself diagnostic. A patient who consistently moves through these four phases, in the same order, with the same character each time, is showing the stereotypical pattern that Rome IV uses to define CVS. Patients whose episodes vary substantially in character from one to the next are usually showing something else. This is one of the questions a careful CVS-aware clinician will ask early: are your episodes more or less the same shape every time, or do they look different from one episode to the next.

The Rome IV criteria for adult cyclic vomiting syndrome are deliberately tight. They are designed to pull out a homogeneous group of patients who genuinely share the same disorder, rather than a loose grouping of anyone who vomits more than usual. Meeting all of the criteria points to CVS with reasonable specificity. Missing one or more should prompt the clinician to think about alternative explanations rather than to bend the criteria to fit. The criteria are pattern-based and history-based. There is no blood test, imaging finding, or endoscopic feature that confirms or refutes CVS by itself.

The four core criteria are: stereotypical episodes of acute onset and short duration (less than one week each); at least three discrete episodes in the prior year, with at least two in the past six months separated by at least one week; complete absence of vomiting between episodes (other symptoms such as mild nausea may occur, but not actual vomiting); and all of the above fulfilled for the last three months, with symptom onset at least six months before diagnosis. Supporting features that are not strictly required but are highly suggestive include a personal or family history of migraine, episodes that recur with predictable triggers (stress, sleep deprivation, menstrual cycle, certain foods), and a strong response of the episode to triptans or other migraine abortives.

The reason for the time qualifier in criterion four (six months from first episode, three months of meeting the full criteria) is to avoid labelling a patient with CVS during a brief, possibly self-limited cluster of vomiting episodes that turns out to have a different explanation. CVS is a chronic disorder. The Rome IV authors built in a deliberate observation window so that the diagnosis carries appropriate weight when it is finally applied. In practice, many adult patients have already crossed this threshold by orders of magnitude before they ever reach a clinician who recognises the pattern.

A common point of confusion is that Rome IV defines CVS as a positive diagnosis based on pattern, not as a diagnosis of exclusion. That said, a focused workup to rule out structural and metabolic mimics is still standard of care, particularly for adult-onset cases. The first-pass workup typically includes basic labs and electrolytes, an upper endoscopy to exclude structural pathology, abdominal imaging to exclude obstruction or biliary pathology, and selectively a gastric emptying study, brain imaging if neurological features are present, and porphyria screening if the history fits. The point of these tests is to exclude alternatives, not to confirm CVS. CVS is confirmed by the pattern.

Adult CVS episodes rarely come out of nowhere. Most patients, when they keep an episode log for a few months, identify recurring triggers that precede their episodes by hours to a couple of days. The trigger profile is patient-specific, but the categories that show up most reliably across published case series and clinical experience are stress (acute or anticipatory), sleep deprivation, menstrual cycle phases, infection, and certain dietary triggers. Many patients have more than one active category. The clinically useful insight is that triggers operate by accumulation. No single trigger is usually sufficient on its own; it is the cumulative load that crosses threshold and starts an episode.

Stress is consistently in the top tier of reported triggers. The pattern is unusual in that it includes positive stressors, not only negative ones. Adult CVS patients describe episodes triggered by anticipated weddings, holidays, exams, work milestones, and travel, in addition to the more obvious negative-stress triggers like family conflict, work crises, and grief. The common factor is autonomic arousal and disrupted sleep around the event, not the emotional valence. This pattern has clinical value because it suggests that brain-gut interventions targeting baseline autonomic reactivity have a mechanistic rationale even when the patient does not report feeling subjectively stressed.

Sleep deprivation is the second most consistently reported trigger. Many adult CVS patients can predict an episode within 48 hours of any night where sleep dropped below their personal threshold (often around five to six hours). This is one of the easiest triggers to act on practically: rigorous sleep protection (consistent bedtime, dark room, no late caffeine, no late screens, alcohol minimisation) reduces episode frequency more reliably than most other lifestyle interventions in this population. The mechanism is plausibly via the same migraine biology that links CVS to migraine, since sleep deprivation is one of the most reliable migraine triggers as well.

Menstrual cycle phase is a major trigger for many female adult CVS patients. The most common pattern is episodes clustering in the perimenstrual window, particularly the late luteal and early menstrual phase, although some patients are predominantly mid-cycle. Tracking the episodes against the cycle for three to six months usually clarifies whether this is a contributing factor for an individual patient. When it is, the clinical implications include the possibility of cycle-targeted prophylactic medication during high-risk windows and sometimes hormonal management discussion with the patient’s primary care provider or gynecologist.

Early-morning onset is one of the most distinctive timing features of adult CVS. Many patients report that their episodes begin in the very early morning hours, often between roughly 4 and 8 a.m., sometimes waking the patient from sleep already nauseated. This timing parallels the morning surge of cortisol and the early-morning increase in autonomic activity that have been described in the broader migraine and brain-gut literature. The practical implication is that prodromal symptoms in the late evening or before bed are worth taking seriously as warning signals, since the acute phase may follow within a few hours.

A subset of patients experience a recognisable prodromal phase that precedes the vomiting by minutes to hours. Common prodromal features include anxiety or a sense of impending doom, lethargy, sweating, pallor, abdominal discomfort, food aversion, and yawning. Recognising the prodrome matters because some abortive interventions, including triptans and ondansetron, are most effective when given during the prodrome rather than waiting for full vomiting to begin. Patients who can reliably identify their prodrome often work with their physician on a home abortive protocol they can deploy at the first warning sign.

The migraine link deserves a paragraph of its own. Adult CVS patients have a markedly elevated personal and family history of migraine compared with the general population. Many CVS episodes have a migraine-like character (photophobia, sound sensitivity, dark and quiet preference, post-episode exhaustion) even in the absence of prominent headache. Pediatric CVS patients commonly transition to typical migraine headaches in adolescence rather than continuing to vomit. The shared biology is thought to involve cortical spreading depression, autonomic dysregulation, mitochondrial energy metabolism, and serotonergic signalling. The clinical relevance is that the medications with the strongest CVS evidence are largely the migraine medications. The link is a guide to therapy, not a curiosity.

Multiple structural features of adult medicine combine to delay the diagnosis of CVS. The first is specialty exposure. Pediatric gastroenterology has a long history of recognising and treating CVS, with established referral pathways and well-known abortive and prophylactic protocols. Adult gastroenterology and emergency medicine have less consistent training on the condition. An adult patient with a stereotypical CVS pattern may be evaluated by a series of clinicians, none of whom have personally treated more than one or two confirmed adult cases.

The second is the episodic nature of the disorder itself. Each episode looks like an isolated acute illness when seen in real time. The patient comes to the ER, is volume-resuscitated, given an antiemetic, kept until they can tolerate fluids, and discharged. The discharge note often reads as gastroenteritis or unspecified vomiting. The next episode looks like another isolated acute illness to a different ER team. The pattern only becomes visible when someone reviews the cumulative history, asks about prior episodes, and notices that the same patient has had this exact presentation eight or fifteen or thirty times.

The third is the predictably normal interval workup. By the time the patient is referred to gastroenterology and an endoscopy and gastric emptying study are performed, the patient is usually in a symptom-free interval. The endoscopy is normal, the gastric emptying is normal, and the patient is told that nothing structural is wrong. This is, of course, exactly what Rome IV would predict, since CVS is a functional disorder defined by pattern rather than by structural pathology. But to a clinician who is not pattern-matching to CVS, normal results read as no diagnosis, which often translates into no further plan and the patient cycling back through the ER for the next episode.

The fourth is cannabis hyperemesis syndrome, which has changed the landscape of adult cyclic vomiting in Canada substantially since legalisation. CHS now accounts for a sizable fraction of adult ER visits for cyclic vomiting in Canadian centres, and many of those patients carry a working diagnosis of CVS that turns out to be wrong. Differentiating CHS from CVS requires a detailed and non-judgmental cannabis history, which not every clinician obtains in full. When the cannabis history is incomplete or the patient under-reports, a CHS patient can spend years on prophylactic amitriptyline that is not helping while continuing the cannabis use that is the actual driver. This is one of the most consequential differential diagnoses to get right.

Across published adult case series, the average diagnostic delay from first episode to a confirmed CVS diagnosis sits in the range of five to nine years. That figure understates the patient experience because it averages across patients who are eventually diagnosed. Patients who are never diagnosed are not in the denominator. The practical implication is that adult patients with a stereotypical, recurrent vomiting pattern often have to be active advocates for their own diagnostic process. Bringing a written summary of episodes (dates, durations, characters, prior workups, prior treatments) to a gastroenterology appointment makes the pattern visible in a way that no single ER chart can.

Abortive treatment is what is delivered during an acute CVS episode to shorten its duration, reduce its severity, or, in the best case, terminate it before the full vomiting phase establishes. This is the part of CVS care that emergency medicine most often gets partially right and rarely gets fully right, because the standard ER vomiting playbook (intravenous fluids plus ondansetron) is necessary but not sufficient for established CVS. The expert-recommended adult abortive protocol layers in additional agents and an environmental component.

The single agent with the strongest evidence base for aborting adult CVS episodes is sumatriptan, given subcutaneously, intranasally, or intravenously depending on availability and tolerance. The earlier in the episode the triptan is given, ideally during the prodrome or within the first hour or two of the acute phase, the more likely it is to abort the episode rather than just blunt it. Patients with a clear prodromal phase often work with their treating physician on a home triptan kit so they can deploy this themselves at the first warning sign without needing ER transport. Triptans are contraindicated in some patients (uncontrolled hypertension, ischemic cardiac or cerebrovascular disease, certain headache patterns), so the home protocol decision is always physician-directed.

Antiemetic coverage in the acute phase is typically led by ondansetron, given intravenously when available, sometimes layered with an additional agent (metoclopramide, prochlorperazine, or a neurokinin-1 antagonist like aprepitant in selected patients). The role of these agents is to reduce vomiting frequency and intensity once the episode is established, rather than to abort it. They are usually combined with intravenous crystalloid fluid resuscitation because patients are often substantially volume-depleted by the time they present.

Lorazepam (or another benzodiazepine, depending on the practice) is a common addition to the adult CVS abortive cocktail. Its role is partly to address the anxiety component of the episode (which is real and is part of the syndrome rather than a separate psychological problem), partly to provide sedation that lets the patient sleep through the worst part of the episode, and partly to reduce the central nausea signal. The dose is usually modest and time-limited. This piece of the protocol is often missing from default ER care because the standard vomiting algorithm does not include a benzodiazepine.

Environment matters more in CVS than in most other vomiting presentations. Adult CVS patients almost universally describe a strong preference for a dark, quiet room during the acute phase, and many report that bright lights, noise, and frequent staff interruptions worsen the episode. Where ER capacity allows, a quiet treatment room with the lights down is part of the recommended protocol. This is similar to how migraine is managed in the same setting and reflects the shared biology.

Prophylactic treatment is what is taken daily, between episodes, to reduce the frequency, severity, and duration of future episodes. For most adult CVS patients with three or more episodes per year (and certainly with monthly or more frequent episodes), prophylactic medication is part of standard care. The choice of agent depends on the patient’s comorbidities, prior medication trials, and tolerance profile, but the broad hierarchy is well-established and largely borrowed from migraine prophylaxis, given the shared biology between the two conditions.

The first-line prophylactic agent for adult CVS is amitriptyline, a tricyclic antidepressant. Doses used in CVS prophylaxis are typically modest by psychiatric standards (often in the 25 to 100 mg per day range) and are titrated up gradually from a low starting dose to manage anticholinergic effects, sedation, and orthostatic symptoms. The expected benefit window is several weeks, not days; most patients should not be considered an amitriptyline non-responder until they have had at least two to three months at an adequate target dose. The mechanism is thought to involve serotonergic and noradrenergic modulation of the brain-gut axis, similar to its effects in migraine prophylaxis and in other functional gut disorders. Amitriptyline carries a list of cautions and contraindications (cardiac conduction issues, glaucoma, urinary retention, certain medication interactions) and is always physician-directed.

Second-line and alternative prophylactic options include topiramate and propranolol, both established migraine prophylactics that have shown benefit in CVS in case series and small trials. Topiramate has a meaningful adverse effect profile (cognitive slowing, paresthesias, weight loss, kidney stones in predisposed patients) that limits its use in some patients but works well for others. Propranolol is generally well tolerated when not contraindicated by asthma or significant bradycardia. The choice between these and other migraine prophylactics is individualised. There is no single right answer; the principle is sequential, time-limited trials of evidence-supported agents until a regimen is found that meaningfully reduces episode burden.

Mitochondrial supplements are an emerging and promising area in CVS prophylaxis, building on the broader hypothesis that CVS shares mitochondrial energy metabolism abnormalities with migraine. The most commonly used agents are coenzyme Q10, riboflavin (vitamin B2), and L-carnitine, each with at least case-series-level evidence in CVS and better evidence in migraine prophylaxis. The effect sizes in published reports are modest individually, and combinations are often used. Supplements are generally well tolerated. The clinical position is that they are reasonable to add as adjuncts, particularly for patients who want a non-prescription component to their regimen, but they are not a replacement for amitriptyline or another evidence-supported prophylactic in patients with significant episode burden.

Trigger reduction belongs in every adult CVS prophylactic plan and operates alongside the medication, not in place of it. The interventions with the most consistent benefit across published case series and clinical experience are sleep regularisation (consistent bedtime, sufficient duration, dark cool bedroom), stress management appropriate to the patient’s life and capacity, dietary trigger avoidance for any individually identified triggers, menstrual cycle awareness with phase-targeted prophylaxis where the pattern fits, alcohol moderation, and rigorous treatment of comorbid conditions like depression, anxiety, and migraine itself. The compounding effect of these interventions is often larger than any single intervention in isolation.

This is the section where it is most important to be honest about what the evidence does and does not say. Gut-directed hypnotherapy and cognitive behavioural therapy for gut conditions both have meaningful evidence bases for irritable bowel syndrome and a few related functional gut disorders. They do not have a comparable evidence base specifically for cyclic vomiting syndrome. CVS-specific trials of either therapy are very small. What they have instead is a mechanistic rationale, a track record of helping with related brain-gut conditions, and case-series and clinical-experience data suggesting that they can reduce inter-episode trigger load in selected patients when added to medical management.

The mechanistic rationale is straightforward. CVS is, at its core, a brain-gut disorder with a strong autonomic component. Episodes are triggered by inputs that converge on the autonomic nervous system, particularly stress, sleep deprivation, and hormonal shifts. Interventions that lower baseline autonomic reactivity and reduce the central anxiety component of the inter-episode period have a plausible mechanism for raising the episode threshold or reducing the number of triggers that reach it. This is the same general logic that applies to brain-gut interventions in IBS, in functional dyspepsia, and in chronic functional pain syndromes.

The largest and most rigorous evidence base for gut-directed hypnotherapy is in IBS, where the Manchester Protocol (a structured 12-session course developed in Whorwell’s clinic) has been studied repeatedly. In the largest single-clinic case series, Miller 2015 (PMID 25736234) reported that 76 percent of refractory IBS patients responded to gut-directed hypnotherapy on the Manchester Protocol in an unselected sample of 1,000 consecutive patients, with response defined as at least 50 percent improvement on validated symptom scoring. Long-term follow-up data from the same clinical tradition show that the effect is durable. Hasan 2019 (PMID 30702396) reported that 76 percent of IBS patients who received gut-directed hypnotherapy maintained their initial symptom improvement at 5+ year follow-up, compared with 65 percent in the medical management comparison group. These figures are for IBS, not CVS, and should not be misread as CVS outcome data.

Cognitive behavioural therapy for gut conditions has a similar profile of strong IBS evidence and small CVS-specific evidence. In the large UK ACTIB trial, Everitt 2019 (PMID 30765267) reported that cognitive behavioural therapy delivered by trained therapists produced clinically significant IBS symptom improvement in 71 percent of patients, with CBT for IBS now a recommended option in NICE and BSG guidelines. CBT for CVS specifically has a slightly larger published evidence base than GDH for CVS, although both are modest by the standards of the IBS literature. In CVS the typical CBT framing emphasises trigger identification and management, anxiety reduction during the symptom-free interval, and structured behavioural interventions around sleep and stress.

The honest framing for CVS specifically is that gut-directed hypnotherapy is not a first-line treatment, is not an abortive treatment, and is not a substitute for prophylactic medication. It is, at most, a reasonable adjunct to add alongside medical management for selected patients who are already on appropriate prophylaxis, who have a stress and autonomic load that plausibly contributes to their trigger pattern, and who are interested in adding a brain-gut intervention to their plan. Patients who are not yet on appropriate medical management should pursue that first. Patients with active undiagnosed cyclic vomiting need a workup before any brain-gut intervention is considered. Patients with suspected cannabis hyperemesis syndrome need cannabis cessation as the first move.

The shape of a gut-directed hypnotherapy course in this practice is the standard Manchester-derived structure: weekly sessions, with the initial commitment set at three sessions to assess fit, and continuation thereafter only if both patient and clinician judge it to be a reasonable adjunct given the patient’s overall clinical picture. The work is collaborative and explicit. The patient knows what is being targeted, why, and what to look for in terms of inter-episode markers (sleep quality, baseline anxiety, prodromal warning sensitivity, recovery quality after episodes). It is not a magic-bullet framing, and any clinician promising one for CVS specifically should be treated with caution.

For context on where this fits in our broader work, our larger evidence base is for gut-directed hypnotherapy for IBS, where the literature is strongest. The mechanism overlaps with what is targeted in CVS through vagal regulation of the brain-gut axis and through the broader stress biology that we discuss in our page on cortisol and IBS. CVS shares features of central sensitisation with IBS, which is part of why brain-gut interventions are mechanistically plausible across the spectrum. And the diagnostic experience of being told your normal endoscopy means nothing is wrong is one we discuss in detail in our piece on conditions commonly misdiagnosed as IBS.

This practice is a gut-directed hypnotherapy clinic. The condition we treat with the most evidence behind us is irritable bowel syndrome and its closely related functional gut disorders, delivered using the Manchester Protocol. Our standard structure is three initial sessions at $220 CAD each, with continuation beyond the initial three optional and decided collaboratively. Sessions are available in person in Calgary or virtually across Canada. None of this is a CVS treatment program in any first-line sense. Being explicit about scope is part of doing this work honestly.

Where we can be a reasonable part of a CVS plan: as an adjunct, for patients who already carry a confirmed CVS diagnosis from a gastroenterologist or neurologist, who are on an appropriate prophylactic regimen, who have a documented stress, sleep, or anxiety contribution to their trigger pattern, and who want to add a brain-gut intervention to reduce inter-episode trigger load. In that context the work focuses on autonomic regulation between episodes, anxiety modulation in the symptom-free interval, prodromal awareness training, and recovery-phase support.

Where we are not the right fit: undiagnosed recurrent vomiting (the right next step is a gastroenterology workup, not a hypnotherapy session); active severe acute episodes (the right next step is your written abortive plan or an emergency department); suspected cannabis hyperemesis syndrome (the right next step is a careful cannabis history with your physician and, if CHS is the working diagnosis, sustained cannabis cessation); patients not on prophylactic medication who would clearly benefit from one (medical management belongs first); and patients looking for a single primary treatment for CVS rather than an adjunct to medical management.

If insurance is part of your planning: hypnotherapy is generally not directly covered under Canadian extended health benefit plans. Some clients can claim related programs (stress management, behavioural change) under a Wellness Spending Account (WSA) if their plan offers one. Coverage rules depend entirely on plan design, so check with your insurance provider before booking. Sessions are paid at time of service. A detailed receipt is provided with the practitioner’s ARCH registration number for any reimbursement your provider may approve.